Sabatini Stefano

INSTITUTE

Università degli Studi di Perugia

Email

stefano.sabatini@unipg.it

ADDRESS

Dipartimento di Scienze Farmaceutiche, via del Liceo 1

PHONE

075 5855130

Developed skills and lines of research

Stefano Sabatini has been an Associate Professor at the University of Perugia, Department of Pharmaceutical Sciences, since 2015. He graduated in Pharmacy from the University of Perugia in 1996 and obtained a PhD in Medicinal Chemistry from the same university in 2001. His research activity aims at the rational design and synthesis, through the application of classical and advanced synthetic methodologies (ultrasound or microwave-assisted, parallel and solid-phase synthesis), of new biologically active compounds, as well as optimization through the study of structure-activity relationships, chemical-physical properties, pharmacokinetics and metabolism of compounds of pharmaceutical interest. His main research topics are antivirals, antibacterials and efflux pump inhibitors as antimicrobial resistance breakers capable of restoring the activity of obsolete antibacterials. He has several national/international collaborations, which have led to the publication of more than 80 articles in peer-reviewed scientific journals. For FFC Ricerca, Stefano Sabatini is involved in the identification and optimization of new antibacterials active against Mycobacterium abscessus, a pathogen that is becoming an increasingly worrying issue in people with cystic fibrosis, in order to be able to carry out studies on animal models in the near future.

Projects funded by FFC Ricerca as Principal Investigator or as Research Manager

FFC#10/2024
Phenotypic medicinal chemistry approaches to identify new anti-Mycobacterium abscessus agents

FFC#17/2017
Identification of new efflux pumps inhibitors able to contrast nontuberculous mycobacterial infections in cystic fibrosis patients

Publications from FFC Research projects

Tommaso Felicetti, Diana Machado, Rolando Cannalire, et al. Modifications on C6 and C7 Positions of 3-Phenylquinolone Efflux Pump Inhibitors Led to Potent and Safe Antimycobacterial Treatment Adjuvants. ACS Infect Dis, 5 (6), 982-1000

Rolando Cannalire, Tommaso Felicetti, Andrea Astolfi, Maria Letizia Barreca, Giuseppe Manfroni, Aurélie Marie-Madeleine Schoubben, Violetta Cecchetti, Miguel Viveiros, Stefano Sabatini. Identification of new efflux pumps inhibitors able to contrast nontuberculous mycobacterial infections in cystic fibrosis patients. The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14 (Suppl 1):5